Clinical Trial Update: Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating AMG 386 (trebananib) with paclitaxel, with or without bevacizumab, as first-line therapy for HER2-negative breast cancer; the study has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AMG-386 (trebananib)
• Bevacizumab (bevacizumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Amgen | Conditions: Locally Recurrent and Metastatic Breast Cancer | Phase 2 | Status: COMPLETED